Tarlatamab for advanced digestive neuroendocrine cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been diagnosed with a neuroendocrine carcinoma (a type of cancer) that started in the digestive system (like stomach, intestines, pancreas) and is advanced (spread or can't be removed with surgery).
- Your cancer must have gotten worse after at least one line of chemotherapy with platinum-based drugs (like cisplatin or carboplatin).
- A tumor sample must show that your cancer cells have a protein called DLL3 on them (the study will test this).
- You must be in fairly good health (able to do daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This study tests an investigational drug called tarlatamab in people with a rare type of cancer called neuroendocrine carcinoma that started in the female reproductive tract (cervix, vulva, or vagina). The goal is to see if tarlatamab can shrink or control the cancer. To participate, your cancer must have progressed after at least one line of platinum-based chemotherapy. You must also have measurable disease and be willing to provide a tumor sample.
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
Hear when a new Advanced Neuroendocrine Carcinomas of The Digestive System trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.